[1]王 蔚,余苏云,吴佳伟,等.肿瘤血管生成抑制剂的治疗局限和策略[J].中国药理学通报,2017,(11):1489-1492.[doi:10.3969/j.issn.1001-1978.2017.11.003]
 WANG Wei,YU Su-yun,WU Jia-wei,et al.Therapeutic limitations and strategies of angiogenesis inhibitors[J].Chinese Pharmacological Bulletin,2017,(11):1489-1492.[doi:10.3969/j.issn.1001-1978.2017.11.003]
点击复制

肿瘤血管生成抑制剂的治疗局限和策略()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2017年11期
页码:
1489-1492
栏目:
讲座与综述
出版日期:
2017-10-20

文章信息/Info

Title:
Therapeutic limitations and strategies of angiogenesis inhibitors
文章编号:
1001-1978(2017)11-1489-04
作者:
王 蔚1余苏云1吴佳伟1黄 帅1吴媛媛12陈文星12王爱云12陆 茵12
南京中医药大学 1.药学院,江苏省中药药效与安全性评价重点实验室;
2.江苏省中医药防治肿瘤协同创新中心,江苏 南京 210023
Author(s):
WANG Wei1 YU Su-yun1 WU Jia-wei1 HUANG Shuai1WU Yuan-yuan12CHEN Wen-xing12 WANG Ai-yun12 LU Yin12
1.School of Pharmacy, Jiangsu Key Lab for Pharmacology and Safety Evaluation of Chinese Materia Medica;
2.Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor,Nanjing University of Chinese Medicine,Nanjing 210023,China
关键词:
肿瘤 血管生成抑制剂 血管正常化 肿瘤干细胞 精准治疗 策略
Keywords:
neoplasm angiogenesis inhibitors vascular normalization cancer stem cell precision therapy strategies
分类号:
R364.3;R730.2;R730.53;R979.1
DOI:
10.3969/j.issn.1001-1978.2017.11.003
文献标志码:
A
摘要:
血管生成抑制剂通过抑制肿瘤血管生成,使肿瘤细胞处在恶劣的生长环境中,而有效阻断肿瘤的发展进程。但在临床应用中,抗血管生成的药物却表现出治疗效果短暂、不良反应较多、适用肿瘤类型少等局限。这些问题制约着药物开发与应用,限制肿瘤治疗的研究进展。诸多文献研究显示,肿瘤细胞可以通过多种机制和途径逃脱血管生成抑制剂的治疗,使血管生成抑制剂“失效”。该文着重分析治疗失效的原因和机制,拟提出对应的解决策略,以改善目前抗血管生成药物疗效,为抗血管生成新药研发及临床用药提供参考。
Abstract:
Angiogenesis inhibitors can make tumor cells in a harsh environment by inhibiting tumor angiogenesis and effectively blocking the tumor progression. However, anti-angiogenic drugs have shown lots of limitations, such as short-term duration, numerous adverse reactions, benefiting only a minority of tumor types and so on. These limitations restrain the development of new drugs and limit the cancer therapies. Many studies have revealed that tumor cells can escape from anti-angiogenic treatments through a variety of ways and mechanisms. In this review, we focus on the reasons behind the failure in treatments, so as to propose solving strategies to improve the current anti-angiogenic drug efficacy and provide reference for new angiogenesis inhibitors and clinical medication.

参考文献/References:

[1] Kümler I, Christiansen O G, Nielsen D L. A systematic review of bevacizumab efficacy in breast cancer[J]. Cancer Treat Rev, 2014, 40(8):960-73.
[2] Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer, 2008, 8(8):592-603.
[3] Rini B I, Atkins M B. Resistance to targeted therapy in renal-cell carcinoma[J]. Lancet Oncol, 2009, 10(10):992-1000.
[4] Ma J, Wang Q, Fei T, et al. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration[J]. Blood, 2007, 109(3):987-94.
[5] 田 超, 范方田, 陈文星,等. 血管紧张素Ⅱ及其1型受体在肿瘤血管生成中的作用研究进展[J]. 中国药理学通报, 2014, 30(5):608-11.
[5] Tian C, Fan F T, Chen W X, et al. Research progress of angiotensin Ⅱ and its type 1 receptor in tumor angiogenesis[J]. Chin Pharmacol Bull, 2014, 30(5):608-11.
[6] Janssen L, Dupont L, Bekhouche M, et al. ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis[J]. Angiogenesis, 2016, 19(1):53-65.
[7] Frentzas S, Simoneau E, Bridgeman V L, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases[J]. Nat Med, 2016, 22(11):1294-302.
[8] Dunleavey J M,Xiao L, Thompson J, et al. Vascular channels formed by subpopulations of PECAM1+ melanoma cells[J]. Nat Commun, 2014, 5:5200.
[9] Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer[J]. Clin Cancer Res, 2010, 16(1):45-55.
[10] Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors[J]. Cancer Res, 2007, 67(8):3560-4.
[11] Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220-31.
[12] Ebos J M, Lee C R, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232-9.
[13] Uemura H, Shinohara N, Yuasa T, et al. A phase Ⅱ study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety[J]. Jpn J Clin Oncol, 2010, 40(3):194-202.
[14] Madsen C D, Sahai E. Cancer dissemination-lessons from leukocytes[J]. Developmental Cell, 2010, 19(1):13-26.
[15] Yang Y J, Na H J, Suh M J, et al. Hypoxia induces epithelial-mesenchymal transition in follicular thyroid cancer: involvement of regulation of Twist by hypoxia inducible factor-1α[J]. Yonsei Med J, 2015, 56(6):1503-14.
[16] De Falco S. Antiangiogenesis therapy: an update after the first decade[J]. Korean J Intern Med, 2014, 29(1):1.
[17] 沈存思, 范方田, 陶 丽,等. 抑癌基因PTEN与肿瘤血管生成研究进展[J]. 中国药理学通报, 2013, 29(5):597-600.
[17] Shen C S, Fan F T, Tao L, et al. Research progress of tumor suppressor gene PTEN and tumor angiogenesis[J]. Chin Pharmacol Bull, 2013, 29(5):597-600.
[18] Park J S, Kim I K, Han S, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment[J]. Cancer Cell, 2017, 31(1): 157-8.
[19] Teulé A, Casanovas O. Relevance of angiogenesis in neuroendocrine tumors[J]. Target Oncol, 2012, 7(2):93-8.
[20] Moserle L, Jiménez-Valerio G, Casanovas O. Antiangiogenic therapies: going beyond their limits[J]. Cancer Discov, 2014, 4(1):31-41.
[21] Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth[J]. Cancer Gene Ther, 2009, 16(4):351-61.
[22] Short J J, Curiel D T. Oncolytic adenoviruses targeted to cancer stem cells[J]. Mol Cancer Ther, 2009, 8(8):2096-102.
[23] Dirks P B. MicroRNAs and parallel stem cell lives[J]. Cell, 2009, 138(3):423-4.
[24] Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist[J]. Nature, 2016, 539(7627):112-7.
[25] Bockhorn J, Prat A, Chang Y F, et al. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models[J]. Cancer Res, 2014, 74(24): 7406-17.

相似文献/References:

[1]刘红椿,杜晓光,耿美玉.锌依赖的组蛋白去乙酰化酶选择性抑制剂研究进展[J].中国药理学通报,2010,(08):0.
 LIU Hong chun,DU Xiao guang,GENG Mei yu.New advances in isoformselective inhibitors of Zn2+dependent histone deacetylase[J].Chinese Pharmacological Bulletin,2010,(11):0.
[2]董宪喆,张鹏,毕明刚.丝/苏氨酸激酶PLK1研究进展[J].中国药理学通报,2010,(03):289.
 DONG Xian zhe,ZHANG Peng,BI Ming gang.Research progress on serine/threonine kinase PLK1[J].Chinese Pharmacological Bulletin,2010,(11):289.
[3]胡世莲.褪黑素抗肿瘤作用及其机制的研究进展[J].中国药理学通报,2008,(04):0.
 HU Shi lian.Melatonin in the treatment of cancer and its mechanism[J].Chinese Pharmacological Bulletin,2008,(11):0.
[4]李德冠,孟爱民.造血干细胞衰老机制研究[J].中国药理学通报,2008,(06):0.
 LI De guan,MENG Ai min.Hematopoietic stem cell senescence[J].Chinese Pharmacological Bulletin,2008,(11):0.
[5]刘新艳,余清声,余红娥,等.中华眼镜蛇毒活性组分诱导内皮细胞凋亡[J].中国药理学通报,2008,(06):0.
 LIU Xin yan,YU Qing sheng,YU Hong e,et al.China cobra venom active factor can induce apoptosis of endothelial cells[J].Chinese Pharmacological Bulletin,2008,(11):0.
[6]杜晶,张励才.TRPM8的研究进展[J].中国药理学通报,2008,(09):0.
[7]张祖斌,顾振纶,蒋小岗,等.smiRNA在肿瘤及肿瘤干细胞中作用的研究进展[J].中国药理学通报,2009,(03):0.
 ZHANG Zu bin,GU Zhen lun,JIANG Xiao gang.The role of miRNAs in the tumor and tumor stem cells[J].Chinese Pharmacological Bulletin,2009,(11):0.
[8]李礼,李静,耿美玉.蛋白激酶C在肿瘤中的作用及其抑制剂研究进展[J].中国药理学通报,2009,(06):0.
 LI Li,LI Jing,GENG Mei yu.The role of protein kinase C in cancer and the progress of inhibitors targeting protein kinase C[J].Chinese Pharmacological Bulletin,2009,(11):0.
[9]刘萍,李静.灵菌红素体外对肿瘤转移相关生物学行为的影响[J].中国药理学通报,2010,(04):501.
 LIU Ping,LI Jing.The effects of Metacycloprodigiosin on tumor metastasisassociated cell behavior in vitro[J].Chinese Pharmacological Bulletin,2010,(11):501.
[10]张燕,肖婷婷,沈祥春.金属硫蛋白的功能及药理作用研究进展[J].中国药理学通报,2010,(06):821.
 ZHANG Yan,XIAO Ting ting,SHEN Xiang chun.The advance role and pharmacological effects of metallothionein[J].Chinese Pharmacological Bulletin,2010,(11):821.

备注/Memo

备注/Memo:
收稿日期:2017-07-11,修回日期:2017-08-10
基金项目:国家自然科学基金资助项目(No 81403260,81573859,81673725,81673648,81703765); 中国博士后科学基金资助项目(No 2014M551639); 江苏省博士后基金资助项目(No 1401138C); 江苏高校优秀科技创新团队计划[苏教科(2013)10号文]; 江苏高校品牌专业建设工程资助项目(No PPZY2015A070); 江苏高校中药学优势学科建设工程资助项目(PAPD)[苏政办发(2014)37号文]; 江苏省中药药效及安全性评价重点实验室国家自然科学基金预研
基金项目(No. JKLPSE201610)
作者简介:王 蔚(1993-),女,硕士生,研究方向:肿瘤血管生成的机制,E-mail:m18652677506@163.com;
陆 茵(1963-),女,博士,教授,博士生导师,研究方向:中药及复方抗肿瘤,通讯作者,Tel:025-85811239, E-mail:luyingreen@126.com
更新日期/Last Update: 2017-10-20